Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last C$0.15 CAD
Change Today 0.00 / 0.00%
Volume 0.0
APC On Other Exchanges
Symbol
Exchange
Venture
OTC US
Frankfurt
As of 3:58 PM 07/6/15 All times are local (Market data is delayed by at least 15 minutes).

advanced proteome therapeuti (APC) Snapshot

Open
C$0.16
Previous Close
C$0.15
Day High
C$0.16
Day Low
C$0.15
52 Week High
09/12/14 - C$0.32
52 Week Low
03/18/15 - C$0.09
Market Cap
16.9M
Average Volume 10 Days
23.3K
EPS TTM
--
Shares Outstanding
112.9M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ADVANCED PROTEOME THERAPEUTI (APC)

Related News

No related news articles were found.

advanced proteome therapeuti (APC) Related Businessweek News

No Related Businessweek News Found

advanced proteome therapeuti (APC) Details

Advanced Proteome Therapeutics Corporation, through its subsidiary, Advanced Proteome Therapeutics Inc., operates as a biotechnology company. It focuses on the development of a patent-pending technology that combines multiple anti-cancer therapies in a single agent to directly target cancer tumors. The company is headquartered in Boston, Massachusetts.

advanced proteome therapeuti (APC) Top Compensated Officers

Founder, Chief Executive Officer, President, ...
Total Annual Compensation: $175.0K
Chief Financial Officer
Total Annual Compensation: --
Compensation as of Fiscal Year 2014.

advanced proteome therapeuti (APC) Key Developments

Advanced Proteome Therapeutics Corporation Appoints Randal Chase to its Board of Directors

Advanced Proteome Therapeutics Corporation announced the appointment of Dr. Randal Chase to its Board of Directors. Dr. Chase currently serves as Chairman of MediMabs and is a member of the Board of Geovax Labs Inc. Most recently, Dr. Chase was Chairman of the Board and Director of Medicago.

Advanced Proteome Therapeutics Announces Promising Results of Triple Combination Immunotherapy Tests

Advanced Proteome Therapeutics Corporation announced the first results of testing a triple combination of immunotherapies in animal models. These preliminary tests were carried out in conjunction with its academic collaborators. The tests compared the effects of the triple combination on tumor retardation and tumor free survival in an animal study with those of an anti-CTLA-4 antibody, a 41-BB antibody, or APC 104, separately, as well as in the various double combinations. The triple combination proved to be superior in retarding growth of tumors from implanted CMS5 tumor cells as well as increasing tumor free survival. Tumor free survival (TFS) was recorded in eight cohorts of mice over several weeks. Tumor free survival was 80% in mice treated with the triple combination (group 8) at the endpoint of the study. By contrast, during the same period, TFS varied in the other groups involving the administration of single entities and double combinations from 0% (group 2), 20% (group 3), 40% (groups 4, 5) to 60% (groups 6, 7). Untreated mice (group 1) did not survive beyond 3 weeks. These tests feature APC 104 in combination with both a checkpoint inhibitor (an anti-CTLA-4 antibody) and the co-stimulatory molecule 41-BB. The latter is known to increase the proliferation of immune cells capable of killing tumor cells and to enhance tumor rejection. APC 104 is a molecule which has been designed to increase the duration of action of APC’s protein delivery system to tumors. The recent clinical success of immunotherapies that interfere with immune checkpoint receptors has resulted in a surge of interest in immunotherapy as a mainstream form of cancer treatment. However, checkpoint inhibition alone, which releases the brakes on the immune system, although strikingly effective in specific subsets of patients, is not sufficient to promote tumor regression in a majority of patients.

Advanced Proteome Therapeutics Corporation Appoints Dr. David Webb to its Corporate Advisory Board

Advanced Proteome Therapeutics Corporation (APC or the company) announced that its Board of Directors has appointed Dr. David Webb to the Company's Corporate Advisory Board. Dr. Webb is currently Adjunct Professor at The Scripps Research Institute (TSRI). At Scripps he has focused on several areas relevant to drug discovery including the detection of circulating tumor cells.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
APC:CN C$0.15 CAD 0.00

APC Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for APC.
View Industry Companies
 

Industry Analysis

APC

Industry Average

Valuation APC Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 11.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ADVANCED PROTEOME THERAPEUTI, please visit www.advancedproteome.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.